The global gout therapeutics market was valued at approximately USD 2.82 billion in 2024 and is expected to grow at 6.5–6.45% CAGR through 2030, reaching between USD 4.13–4.13 billion by that time Alternative forecasts (e.g., Spherical Insights) suggest a higher CAGR up to 12.7%, with a market value reaching USD 7.1 billion by 2032 Forecast variances are driven by novel therapies, biologic adoption, and rising global prevalence of gout.

Sample Report :  https://www.datamintelligence.com/download-sample/Gout Therapeutics Market

 Market Drivers

1. Rising Prevalence & Aging Population
   The age standardized gout prevalence reached ~659.3 per 100,000 globally in 2020, with men especially at risk (1,030/100k vs. 316/100k in women) Aging demographics and lifestyle shifts like high purine diets and obesity fuel increasing incidence, especially in North America and Asia Pacific . 
   
   

2. First Line NSAIDs Dominate
   NSAIDs—drugs like naproxen and indomethacin—contributed ~42–46% of market share in 2024, maintaining dominance for acute flare management due to accessibility and affordability 

3. Urate Lowering Agents & Pipeline Expansion
   Including xanthine oxidase inhibitors and uricosurics (e.g., febuxostat, dotinurad, topiroxostat), this class is the fastest growing. New entrants like dotinurad (approved in Japan, expanding globally) offer selective urate reabsorption inhibition 

4. Biologics for Refractory Gout
   Intravenous pegloticase (Krystexxa) and IL 1 blockers like canakinumab are gaining traction for chronic, refractory cases. Pegloticase is now marketed by Amgen in the U.S.; canakinumab received FDA approval for gout flares in 2023 Technological & Personalized Medicine Advances
   Precision dosing guided by genomics, safer formulations, and once daily dosing aim to improve adherence. Combination drugs like arhalofenate (dual anti inflammatory and urate lowering) are entering the pipeline 

5. Strong Pipeline and R&D Investment
   Firms like Horizon, Regeneron, Takeda, and Teijin are developing new therapies (e.g., dotinurad, SEL 212) and biologic/novel xanthine oxidase inhibitors, enhancing future market growth 

Customize Report : https://www.datamintelligence.com/customize/Gout Therapeutics Market

 Regional Breakdowns

🇺🇸 North America

• Dominated ~47.5% of global market share in 2024
  
  

• The U.S. supports treatment of over 8 million gout patients, aided by robust reimbursement systems and rapid adoption of both generics and novel therapies 

• Generics, like colchicine and allopurinol, now account for 97% of volume; brand players shift focus due to competitive pressures
  
  

• U.S. awareness campaigns—such as by Horizon in 2023—boost education around gout and kidney health

🇯🇵 Japan

• Reached USD 102.1 million in 2023 and projected to expand to USD 169.7 million by 2030 (7.5% CAGR) 

• NSAIDs dominate revenue, but urate lowering therapies are growing more rapidly Approvals for novel drugs—dotinurad (2020) and topiroxostat (2013)—highlight Japan’s early adoption of new treatment mechanisms Japan is the leading Asia Pacific market, benefiting from regulatory support, elder demographics, and proactive EHR driven treatment plans .
  
  

Buy this report: https://www.datamintelligence.com/buy-now-page?report=Gout Therapeutics Market

 Asia Pacific

• Grew to USD 557.7 million in 2023; expected to reach USD 912.7 million by 2030 (7.3% CAGR

• Thailand is the fastest growing country in the region .
  
  

 Key Trends & Pipeline Highlights

• Dotinurad (Urece): URAT1 inhibitor approved in Japan, expanding into North America and Europe 

• Pegloticase: Managing tophaceous gout; now under Amgen's U.S. mark for enhanced access

• Canakinumab: Gaining FDA indication for acute gout flare control (2023) Arhalofenate: Experimental dual mode agent—lowering uric acid and inflammation Topiroxostat: Japanese xanthine oxidase inhibitor with strong local uptake 9

 Growth Opportunities

 Strategic Recommendations

1. Forge Pharma–Telehealth Partnerships
   Bundle therapeutics with apps managing serum urate, reminders, and adherence feedback—appealing to tech savvy elderly patients.
   
   

2. Push Biologic Access Programs
   Work with healthcare payers in the U.S. and Japan to support reimbursement of costly but effective biologic agents in refractory patients.
   
   

3. Localize Market Trials & Awareness Campaigns
   Engage U.S. centers (e.g., GUAES) and Japanese clinics for gout education, co marketing novel drugs like dotinurad and topiroxostat.
   
   

4. Drive Rural & Digital Access in Asia
   Collaborate in Asia with generic manufacturers and telepharmacies to enhance reach in emerging markets.
   
   

5. Focus on Personalized Therapeutics
   Develop compliance tools and pharmacogenomic strategies to reduce adverse events (e.g., febuxostat’s cardiovascular warnings) 

Subscribe report :  https://www.datamintelligence.com/buy-now-page?report=Gout Therapeutics Market

 Conclusion

The gout therapeutics market is entering a pivotal era. Anchored by widespread NSAID use, but energized by urate lowering agents, biologics, and precision medicine, it’s forecast to expand from ~USD 2.8 billion in 2024 to between USD 4.1–7.1 billion by 2030–2032. North America and Japan will remain key players, with Asia Pacific surging.

Pharma leaders that introduce biologics, advocate for personalized therapies, form digital health integrations, and support access in emerging markets are well positioned for leadership in this rapidly evolving space.